Clinical data for first combination of two T cell engagers in a solid tumor will be presented in a poster on Friday, November 6, and an oral presentation on November 7 The poster and oral presentations will include additional safety and efficacy…
Feasibility and innate-to-Th1 pharmacodynamics for candidate OAP-101, built on proprietary OmniAntigen™ Platform (OAP) OAP enables systematic immu... Novastra Therapeutics to Present First-in-Human Data for OAP-101 in Checkpoint-Refractory Advanced Melanoma at SITC 2026 Annual Meeting - Feasibility and innate-to-Th1 pharmacodynamics for candidate OAP…
Moderna Chief Executive Stéphane Bancel thinks investors are wrong about the company’s cancer vaccine. Moderna’s stock fell sharply over the past few days after data emerged about its cancer vaccine that investors found disappointing, though researchers called it breakthrough. Bancel…
The use of a 31-gene genetic expression profile helps to identify patients with melanoma at low risk of progression following surgery, resulting in fewer follow-up clinic visits, according to research published in JAMA Surgery. The National Comprehensive Cancer Network (NCCN)…
2026-10-28. The following slide deck was published by Moderna, Inc. in conjunction with this event.
Moderna (MRNA) and Merck (MRK) just released trial results for their joint vaccine against melanoma, the deadliest form of skin cancer. The results were positive, and even doctors praised the news. However, investors reacted differently to the news. On October…
Iovance Biotherapeutics reported final Phase 2 data at ESMO 2026 showing lifileucel plus pembrolizumab in frontline advanced melanoma reached a 62.5% objective response rate, a 29.2% complete response rate and median overall survival not yet reached, with safety in line with known profiles. The…
A new review synthesizes evidence that gut microbiota composition and metabolites such as short-chain fatty acids modulate immune responses to mRNA vaccines, while cautioning that most data remain observational.
The FDA’s approval of an mRNA flu shot presents a new, long-awaited option—and raises big questions about the future of flu vaccines. On August 5, the US Food and Drug Administration approved Moderna’s mFLUSIVA, the first influenza vaccine to use…
BOSTON, October 28, 2026--Strand Therapeutics doses first patients with STX-003, a systemic programmable mRNA therapy designed for tumor-selective activation Oops, something went wrong U.S. markets close in 3h 36m Strand Therapeutics Doses First Patients with STX-003, a Systemic Programmable mRNA Therapy Designed for Tumor-Selective…
mRNA beyond COVID: personalized cancer vaccines, mRNA flu and other vaccines, mRNA for protein replacement, lipid nanoparticles and the fight over mRNA funding.
An article joins this feed when it matches these terms. Each one is also a search of its own.